Release time：Jul 20, 2021
From July 15th to 16th, 2021, Mabwell held the 4th Technology Conference on "Harmony and Advancement, Deep Cultivation and Empowerment" in Jiaxing, Zhejiang Province.
In order to promote the construction of new drug R&D system of Mabwell, empower the team, and continuously improve the R&D management level, the Mabwell Conference has been held since July 2018, at which the business backbones of each R&D line came together in the middle of each year to summarize and review the R&D work and share and exchange the R&D strategies and project management experience. The four conferences have witnessed the development of Mabwell from its new establishment to growth into a specialized, commercialized and internationalized company.
At this Conference, Dr. Liu Datao, the founder and CEO of Mabwell , gave a keynote report entitled "Harmony and Advancement, Deep Cultivation and Empowerment". In the report, Dr. Liu Datao expounded the corporate culture and corporate positioning, reviewed the implementation of the first five-year plan, and looked forward to the corporate development direction. The Project Management Department of Mabwell presented the R&D work report for 2020-2021, and analyzed the R&D pipeline, progress status, team output, annual performance highlights and construction of the R&D project management system as a whole. By centering on the principle of "Begin with the End in Mind, and Perform Comprehensive Layout" and under the host of Guo Yinhan - Chief R&D Officer, Zhang Jinchao - Chief Technical Officer, Wang Shuhai - Chief Medical Officer, Hu Huiguo - Chief Commercial Officer and Chen Xi - Vice President, all teams in the fields of new molecule discovery research, preclinical and exploratory clinical pharmaceutical research, manufacturing research, clinical studies, pharmacology, intellectual property rights, new drug registration, business development and drug marketing jointly conducted the discussion on new drug R&D strategies.
At the conference, Mabwell awarded outstanding individuals and advanced teams in new drug R&D, new drug registration, intellectual property rights and business development.
